Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could blocking a hormone be the key to menopausal bone health?

NCT ID NCT07254429

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether blocking a hormone called LH can improve bone health in menopausal women. 192 women with moderate-to-severe hot flashes will receive either a GnRH analog, estrogen, testosterone, or a placebo for 8 weeks. The goal is to find a safer alternative to estrogen therapy for preventing bone loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Triptorelin (GnRH analog), Estradiol, Testosterone
What this could lead to
If successful, this could point toward a new hormone-blocking treatment for menopausal bone loss that avoids the risks of estrogen therapy.
What could go wrong
This is a small, early-phase trial with only 192 participants over 8 weeks. The results may not apply to all women, and the GnRH analog may cause side effects like hot flashes or mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 192 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women \>40 years and ≤65 at screening visit * A body mass index between 18-35 * Confirmed menopause * Method 1 * Spontaneous amenorrhea for ≥12 consecutive months * Negative urine hCG test * Method 2 * Spontaneous amenorrhea for ≥6 months * FSH \>30 mIU/L * Negative urine hCG test * Moderate to severe vasomotor symptoms (VMS) * Within the 7 days prior to randomization, participants must report ≥ 14 moderate to severe VMS per week Exclusion Criteria: * Current or previous hormone replacement therapy (HRT) * Vaginal estradiol/vaginal inserts (e.g. Vagifem®) can be used, but will have to be pause 2 weeks prior to randomization and throughout the study period * Menopausal Hormone Therapy (MHT) can be used by participants, but must be paused 6 weeks prior to inclusion. * Current or previous cancer diagnosis * Except for basal cell carcinoma * Known BRCA gene mutation * Current hyperthyroid disease * Osteoporosis * Major psychiatric diagnosis including ongoing medication e.g. selective serotonin re-uptake inhibitors (SSRIs) * Known prolonged QT or other known clinically significant abnormal ECG, including taking medication that can prolong QT interval (e.g. sotalol, dronedarone, amiodarone, methadone, and several antipsychotic drugs) * Previous myocardial infarction or heart failure * Previous thromboembolic event * The use of opioids, anticoagulating treatment or unwilling to pause fish oil/Omega-3 supplements 3 days prior visit 1 and 3 * Current alcohol or drug abuse * Hypertension treated with more than two drugs * Severe history of allergy, hypersensitivity, or intolerance to drugs * Moderate to severe liver and kidney disease (eGFR \<60 mL/min) * Diagnosed with type 1 or 2 diabetes * Chronic diseases requiring immunomodulatory treatments such as rheumatoid arthritis, inflammatory bowel disease, and vasculitis etc. * Known uterine fibroids, Endometriosis, Systemic lupus erythematosus (SLE), otosclerosis, severe migraine or sleep apnea * Known Epilepsy or previous seizures or convulsive disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone markers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev.

    RECRUITING

    Herlev, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.